Better Therapeutics, Inc.
BTTX · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $841 | $797 | $0 | $0 |
| Gross Profit | -$841 | -$797 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,833 | $2,240 | $3,389 | $3,049 |
| G&A Expenses | $2,116 | $3,081 | $3,432 | $3,578 |
| SG&A Expenses | $3,508 | $4,785 | $5,536 | $5,273 |
| Sales & Mktg Exp. | $1,392 | $1,704 | $2,104 | $1,695 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4,500 | $7,025 | $8,925 | $8,322 |
| Operating Income | -$5,341 | -$7,025 | -$8,925 | -$8,322 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$518 | -$563 | -$431 | -$439 |
| Pre-Tax Income | -$5,859 | -$7,588 | -$9,356 | -$8,761 |
| Tax Expense | $3 | $1 | $1 | $4 |
| Net Income | -$5,862 | -$7,589 | -$9,357 | -$8,765 |
| % Margin | – | – | – | – |
| EPS | -0.15 | -0.24 | -0.39 | -0.37 |
| % Growth | 37.5% | 38.5% | -5.4% | – |
| EPS Diluted | -0.15 | -0.24 | -0.39 | -0.37 |
| Weighted Avg Shares Out | 38,495 | 31,215 | 23,827 | 23,745 |
| Weighted Avg Shares Out Dil | 38,495 | 31,215 | 23,827 | 23,746 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $518 | $563 | $431 | $439 |
| Depreciation & Amortization | $841 | $797 | $755 | $721 |
| EBITDA | -$4,500 | -$6,228 | -$8,170 | -$7,601 |
| % Margin | – | – | – | – |